- Home
- GGAL vs CORT Comparison
GGAL vs CORT Comparison
Compare GGAL & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | CORT |
|---|---|---|
| Founded | 1905 | 1998 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GGAL | CORT |
|---|---|---|
| Price | $56.04 | $35.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $67.50 | ★ $111.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.6M |
| Earning Date | 03-07-2023 | 02-25-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.35 | ★ 0.87 |
| Revenue | ★ $3,630,934,738.00 | $741,172,000.00 |
| Revenue This Year | $12.64 | $23.96 |
| Revenue Next Year | $18.04 | $43.40 |
| P/E Ratio | ★ $16.82 | $40.01 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $25.89 | $32.99 |
| 52 Week High | $74.00 | $117.33 |
Technical Indicators
Market Signals| Indicator | GGAL | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 16.99 |
| Support Level | $52.36 | $32.99 |
| Resistance Level | $56.28 | $85.34 |
| Average True Range (ATR) | 1.93 | 4.09 |
| MACD | 0.15 | -5.91 |
| Stochastic Oscillator | 96.93 | 4.61 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.